Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fixed low dose versus concentration-controlled initial tacrolimus dosing with reduced target levels in the course after kidney transplantation: results from a prospective randomized controlled non-inferiority trial (Slow & Low study).
Stumpf J, Budde K, Witzke O, Sommerer C, Vogel T, Schenker P, Woitas RP, Opgenoorth M, Trips E, Schrezenmeier E, Hugo C; German S&L Study. Stumpf J, et al. Among authors: budde k. EClinicalMedicine. 2023 Dec 22;67:102381. doi: 10.1016/j.eclinm.2023.102381. eCollection 2024 Jan. EClinicalMedicine. 2023. PMID: 38152417 Free PMC article.
Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients.
Sommerer C, Glander P, Arns W, Ariatabar T, Kramer S, Vogel EM, Shipkova M, Fischer W, Liefeldt L, Hackenberg R, Schmidt J, Zeier M, Budde K. Sommerer C, et al. Among authors: budde k. Transplantation. 2011 Apr 15;91(7):779-85. doi: 10.1097/TP.0b013e31820d3b9b. Transplantation. 2011. PMID: 21297553 Clinical Trial.
A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year.
Arns W, Sommerer C, Glander P, Ariatabar T, Porstner M, May C, Paulus EM, Shipkova M, Fischer W, Liefeldt L, Hackenberg R, Schemmer P, Domhan S, Zeier M, Budde K. Arns W, et al. Among authors: budde k. Clin Nephrol. 2013 Jun;79(6):421-31. doi: 10.5414/CN107908. Clin Nephrol. 2013. PMID: 23611518 Clinical Trial.
Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F, Budde K, Zeier M, Wüthrich RP, Reinke P, Eisenberger U, Mühlfeld A, Arns W, Stahl R, Heller K, Witzke O, Wolters HH, Suwelack B, Klehr HU, Stangl M, Hauser IA, Nadalin S, Porstner M, May C, Paulus EM, Sommerer C; ZEUS Study Investigators. Lehner F, et al. Among authors: budde k. Transpl Int. 2014 Nov;27(11):1192-204. doi: 10.1111/tri.12411. Epub 2014 Aug 20. Transpl Int. 2014. PMID: 25070687 Free article. Clinical Trial.
Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease.
Zschiedrich S, Budde K, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hoerl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Lindner TH, Faerber L, Wimmer P, Stork R, Eckardt KU, Walz G. Zschiedrich S, et al. Among authors: budde k. Nephrol Dial Transplant. 2016 Feb;31(2):284-9. doi: 10.1093/ndt/gfv077. Epub 2015 Apr 1. Nephrol Dial Transplant. 2016. PMID: 25832108
662 results